Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1

References

• Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291:1-13; PMID:23772560; http://dx.doi.org/10.1111/nyas.12180
   PubMed Web of Science ®Google Scholar
• Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015; 3:7; PMID:25806106; http://dx.doi.org/10.1186/s40425-015-0051-7
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3:9; PMID:15723705; http://dx.doi.org/10.1186/1479-5876-3-9
   PubMed Web of Science ®Google Scholar
• Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013; 6:74; PMID:24283718; http://dx.doi.org/10.1186/1756-8722-6-74
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-24; PMID:17606980; http://dx.doi.org/10.1093/intimm/dxm057
   PubMed Web of Science ®Google Scholar
• Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AW, Graham CH. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 2016; 7:10557-67; PMID:26859684; http://dx.doi.org/10.18632/oncotarget.7235
   PubMed Web of Science ®Google Scholar
• Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003; 81:281-7; PMID:12721664; http://dx.doi.org/10.1007/s00109-003-0430-2
   PubMed Web of Science ®Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54:307-14; PMID:15599732; http://dx.doi.org/10.1007/s00262-004-0593-x
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2:662-73; PMID:24403232; http://dx.doi.org/10.1002/cam4.106
   PubMed Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9; PMID:22658126; http://dx.doi.org/10.1056/NEJMe1205943
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016; 21:462-73; PMID:26899259; http://dx.doi.org/10.1007/s10147-016-0959-z
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Exp Rev Clin Pharmacol 2016; 9:1571-81; PMID:27623999; http://dx.doi.org/10.1080/17512433.2016.1236681
   Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, In vitro functional studies, and cynomolgus macaque toxicology. PloS One 2016; 11:e0161779; PMID:27610613; http://dx.doi.org/10.1371/journal.pone.0161779
   PubMed Web of Science ®Google Scholar
• Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Exp Opin Biol Ther 2016; 16:389-96; PMID:26750801; http://dx.doi.org/10.1517/14712598.2016.1141195
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Li Q, Wang Z. Bispecific antibodies in cancer immunotherapy. Hum Vaccines Immunother 2016; 1-10; PMID:27249163; http://dx.doi.org/10.1080/21645515.2016.1141845
   Web of Science ®Google Scholar
• Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure 2015; 23:2341-8; PMID:26602187; http://dx.doi.org/10.1016/j.str.2015.09.010
   PubMed Web of Science ®Google Scholar
• Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A 2008; 105:3011-6; PMID:18287011; http://dx.doi.org/10.1073/pnas.0712278105
   PubMed Web of Science ®Google Scholar
• Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288:11771-85; PMID:23417675; http://dx.doi.org/10.1074/jbc.M112.448126
   PubMed Web of Science ®Google Scholar
• Wu PW, Li J, Kodangattil SR, Luxenberg DP, Bennett F, Martino M, Collins M, Dunussi-Joannopoulos K, Gill DS, Wolfman NM, et al. IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J Mol Biol 2008; 382:1168-83; PMID:18675824; http://dx.doi.org/10.1016/j.jmb.2008.07.046
   PubMed Web of Science ®Google Scholar
• Waneskog M, Bjerling P. Multi-fragment site-directed mutagenic overlap extension polymerase chain reaction as a competitive alternative to the enzymatic assembly method. Anal Biochem 2014; 444:32-7; PMID:24084380; http://dx.doi.org/10.1016/j.ab.2013.09.021
   PubMed Web of Science ®Google Scholar